Literature DB >> 3876905

Acute leukemia presenting as arthritis in children.

F T Saulsbury, H Sabio.   

Abstract

The clinical and laboratory features of six children with arthritis as the presenting manifestation of acute leukemia are reviewed. Asymmetric arthritis involving the large joints of the extremities was the dominant clinical feature in all patients. Despite the presence of antinuclear antibody in three patients, other laboratory features, particularly hematologic abnormalities, served as clues to the diagnosis of leukemic arthropathy in most patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876905     DOI: 10.1177/000992288502401103

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  6 in total

1.  The orthopaedic presentation of acute leukaemia in childhood.

Authors:  J Chell; J A Fernandes; M J Bell
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

2.  Case report 761. Acute lymphocytic leukemia.

Authors:  S V Patrone; C S Resnik; S C Aisner; J W Young
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

Review 3.  Rheumatological manifestations of haematological diseases.

Authors:  S Menon; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

4.  Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset.

Authors:  Mirian S Tamashiro; Nádia Emi Aikawa; Lucia Maria A Campos; Lílian Maria Cristofani; Vicente Odone-Filho; Clovis A Silva
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Commentary - ordering lab tests for suspected rheumatic disease.

Authors:  James N Jarvis
Journal:  Pediatr Rheumatol Online J       Date:  2008-11-17       Impact factor: 3.054

Review 6.  Clinical utility of antinuclear antibody tests in children.

Authors:  Julie L McGhee; Lauren M Kickingbird; James N Jarvis
Journal:  BMC Pediatr       Date:  2004-07-09       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.